Introducing BeFake: The AI-Powered Social Media App from Alias Technologies, Now Out of Stealth Mode with $3M in Seed Funding!

Welcome to the World of BeFake! The Rise of Alias Technologies SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) — Alias Technologies has officially emerged from stealth mode with the launch of BeFake, an innovative AI-driven social media app that is revolutionizing the way we connect with our friends and share our everyday moments. With $3M…

Read More

Breaking News: Foghorn Therapeutics Doses First Patient in Revolutionary AML Study!

Today, a groundbreaking development in the field of biotechnology has taken place. Foghorn® Therapeutics Inc., a clinical-stage biotechnology company, has announced the dosing of the first patient in the Phase 1 study of FHD-286 in combination with decitabine or cytarabine in relapsed and/or refractory acute myeloid leukemia (AML). This news marks a significant milestone in…

Read More

Revolutionizing Heart Health: HeartSciences Partners with FJ Medical Denmark for Global Distribution

HeartSciences Signs Distribution Agreement with FJ Medical, Denmark Southlake, TX, Aug. 31, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has signed…

Read More

Join the Fun: Beam Therapeutics Set to Take the Stage at Exciting September Investor Conferences!

Welcome to the Beam Therapeutics Fireside Chat Extravaganza! Gather ’round, friends, it’s time for some genetic medicine gossip! Hey there, gene-editing enthusiasts! Guess what? Your favorite biotechnology company, Beam Therapeutics Inc., is gearing up for some exciting fireside chats at the upcoming September investor conferences! That’s right, mark your calendars for Thursday, September 7th at…

Read More

Unlocking the Potential of NE3107: BioVie’s Virtual KOL Event on Alzheimer’s Disease Set for September 7, 2023

BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023 CARSON CITY, Nev., Aug. 31, 2023 (GLOBE NEWSWIRE) Introduction BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, has announced it will…

Read More